News

March 18, 2024

Vator Securities acts as Sole Bookrunner in LifeClean International 16 MSEK Directed Issue

LifeClean International offers sustainable disinfection, sanitation and cleaning solutions that address several of our biggest challenges, such as antimicrobial resistance, contamination and PFAS pollution. Among other things, LifeClean is behind the world's first climate-neutral chemical production, the world's richest detergent and a unique, patented and more environmentally friendly chemical formula based on chlorine dioxide. The chemical technology is the basis for a proven effective method for PFAS sanitation and is also verified as a spore-, fungus-, biofilm-, bacteria- and virus-killing surface disinfection. The Company operates two production facilities in Sweden, certified according to ISO 13485, ISO 14001 and ISO 9001.

» Read more

March 11, 2024

Vator Securities acts as Sole Bookrunner in ChromoGenics 16 MSEK Directed Issue

ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films. The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass.

» Read more

February 23, 2024

Vator Securities acts as Sole Global Coordinator in Kancera 122 MSEK Rights Issue

Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The company is a leader in drug development of small molecule fractalkine blockers. Kancera is developing two drug candidates with the same mode of action; the CX3CR1 antagonists KAND567 and KAND145.

» Read more

February 9, 2024

Vator Securities acts as Sole Global Coordinator and Bookrunner in Alligator Bioscience 151 MSEK Rights Issue

Alligator is a clinical-stage research and development-based biotechnology company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-directed immunotherapies, specifically agonistic mono- and bispecific antibodies. Immunotherapy is a type of treatment that stimulates the patient’s own immune system to cure cancer. Alligator is active in the drug development phases ranging from concept and early drug discovery up to and including Phase 2 clinical studies involving patients. This includes the development and optimization of novel drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients.

» Read more

January 2, 2024

Vator Securities advises Fenix Family in Capital Raise

Fenix ​​Family's digital B2B2C service enables customers of banks and asset managers to estate plan in a simple, fast, and safe way. This means that, based on a will, Fenix ​​draws up a unique life plan for the end customer, their family, assets, and any loans. The plan includes legal agreements, tips on financial services and practical preparations for the family to have peace of mind here and now as well as in the future. The company's subscribers have grown strongly since launch. Growth is driven by the security Fenix ​​creates for end consumers and partners' needs to digitalize and personalize an increasingly important aspect of financial services: estate planning.

» Read more

December 23, 2023

Vator Securities advises Chordate Medical on 42 MSEK Rights Issue

Chordate Medical is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region.

» Read more

December 19, 2023

Vator Securities advises InCoax Networks on 53 MSEK Rights Issue

InCoax Networks re-purposes existing property coaxial networks in fiber and fixed wireless access (FWA) extension deployments for Communication Service Providers (CSP) globally. The technology is a high performance, future proof, reliable and cost-effective complement, that reduces installation time and improves take-up rate, to boost digital inclusion and Internet access for all. 

» Read more

December 18, 2023

Vator Securities advises Svenska Aerogel on 51 MSEK Rights Issue

Svenska Aerogel manufactures and commercializes the mesoporous material Quartzene®. Svenska Aerogel's business concept is to meet the market's need for new materials that are in line with global sustainability objectives. Quartzene® is flexible and can be tailored to different applications to add essential properties to an end product. The Company's vision is to be the most valued business partner providing pioneering material solutions for a sustainable world.

» Read more

December 15, 2023

Vator Securities advises Saniona on 140 MSEK Rights Issue

Saniona is an epilepsy focused clinical-stage biopharmaceutical company engaged in the discovery and development of medicines modulating ion channels. Saniona’s epilepsy pipeline includes the Phase 2 ready asset SAN711 positioned for treatment of absence seizures, the preclinical development compound SAN2219 for acute repetitive seizures and the drug-discovery program on Kv7 modulators for refractory focal onset seizures. Outside epilepsy Saniona has three clinical programs, which are positioned for partnering. The most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity in Mexico by Saniona’s partner Medix, whereas Tesomet™ is ready for Phase 2b for rare eating disorders, and SAN903 is ready for Phase 1 for inflammatory bowel disease.

» Read more

December 13, 2023

Vator Securities advises Howwe Technologies on 15 MSEK Private Placement

Howwe has developed a market-leading SaaS platform that accelerates customers’ execution & financial results. The SaaS application helps CEOs and their underlying organization with digital strategy execution. The market for digital strategy execution is underdeveloped with an apparent need for an application to drive execution and digital transformation.

» Read more

December 6, 2023

Vator Securities advises ESTRID on 93 MSEK Private Placement

ESTRID is a fast-growing Scandinavian razor and body care brand disrupting the European shaving market by gaining market share against established incumbents by offering fairly priced, high-quality products which are 100% vegan. ESTRID reported SEK 438 million revenue in 2022, a stunning 93% growth compared to 2021. Rapid European growth continues in 2023 with stronger profitability and the Nordics, Germany and the UK as key markets.

» Read more

November 28, 2023

Vator Securities advises ZignSec on 9 MSEK Directed Share Issue

ZignSec is a technology group in the rapidly growing RegTech industry. The company provides a SaaS platform with real-time digital customer knowledge and ID verification solutions with global reach. The solutions are used by companies who in turn can optimise their processes to "onboard" both business customers and consumers while ensuring compliance with ever-changing local and global regulatory requirements for Know Your Customer (KYC) and Anti Money Laundering (AML).

» Read more

November 21, 2023

Vator Securities advises WntResearch on 56 MSEK Rights Issue

WntResearch is an oncology biotech company that develops new therapies to counteract the development of cancer metastases. The company’s research is focused on studying the endogenous protein WNT5A, which has been shown in scientific studies to affect the ability of tumor cells to move and spread in the body. WntResearch’s drug candidate Foxy-5 is a peptide that mimics the function of WNT5A with the aim of reducing the mobility and spread of cancer cells and thereby preventing metastases from occurring.

» Read more

October 12, 2023

Vator Securities advises Fragbite Group on 22 MSEK Directed Share Issue

Fragbite Group AB (publ) is a Swedish corporate group with a portfolio of established subsidiaries that develop, adapt and publish games and esports content within GAMING, ESPORTS and WEB3. Their products are developed for both traditional platforms – PC, mobile and console – and modern web3 platforms built on blockchain technology. The purpose of the directed issue is mainly to finance the acquisition of Fall Damage and the continued operation of Fall Damage and the development of its tactical First Person Shooter (“FPS”) game ALARA Prime until launch.

» Read more

June 30, 2023

Vator Securities advises Medfield Diagnostics on 33 MSEK Rights Issue

Medfield is a medical technology company that has developed the product MD100 Strokefinder, a device powered by AI and microwave technology that can distinguish stroke patients from healthy individuals and differentiate between strokes caused by a clot and those caused by a hemorrhage. By routing the patient directly to a stroke or trauma center, qualified treatment can be started much faster, leading to time savings, faster care, better outcomes, and lower healthcare costs. The company generates revenue through the sale of the MD100 system, software upgrades, service and maintenance, and disposable materials.

» Read more

June 28, 2023

Vator Securities advises Moberg Pharma on 100 MSEK Rights Issue

Moberg Pharma AB (publ) is a Swedish pharmaceutical company with a focus on the commercialization of proprietary medicines based on proven substances. The company's main asset is MOB-015 - a new topical treatment for nail fungus. Phase 3 clinical studies of more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners on site in Europe and Canada, among others. MOB-015 was recommended for market approval in the EU June 2023.

» Read more